Ischemia and infarction in STEMI patients with multivessel disease: Insights from the CvLPRIT Nuclear Substudy

Andrew D. Kelion (Lead Author), Mini V. Pakkal, Fahmid U. Chowdhury, James D. Birchall, Katherine L. Dixon, Florence Y. Lai, Damian J. Kelly, Marcus Flather, Gerry P. McCann, Anthony H. Gershlick

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
10 Downloads (Pure)


The CvLPRIT (Complete versus Lesion-only PRimary PCI Trial) trial was undertaken in 7 UK centers (1,2). Patients with ST-segment elevation myocardial infarction (STEMI) and multivessel coronary stenoses were randomized to primary percutaneous coronary intervention (PPCI) to the infarct-related artery (IRA) only, or complete revascularization. At 12-month follow-up, the rate of the combined primary endpoint (all-cause mortality, recurrent MI, heart failure, ischemia-driven revascularization) was lower after complete revascularization. All surviving patients were asked to undergo myocardial perfusion scintigraphy (MPS) 6 to 8 weeks post-admission. It was expected that this a priori nuclear substudy would provide mechanistic insights into the outcome of the main trial, and help to define the clinical role of MPS in the PPCI era.
Original languageEnglish
Pages (from-to)2698-2699
Number of pages2
JournalJournal of the American College of Cardiology
Issue number22
Publication statusPublished - 7 Jun 2016

Cite this